Cardiovascular Sciences, Inc. to Exhibit Health Products at 50-Plus Expo

  
    
  
  
    
      Cardiovascular Sciences, Inc. (PINK SHEETS: CVSC) proudly announces it 
      has been accepted to exhibit its line of unique health promotion 
      products at the 12th Annual Fifty-Plus Expo at 
      Times Square’s Marriott Marquis in New York 
      City (www.FiftyPlusExpo.net). 
      The annual event will be held Sunday, November 9th, 
      11 AM through 5 PM. It will feature presentations from several notable 
      leaders in the field of health promotion, including Dr. Oz Garcia, David 
      Dworkin and keynote speaker, Marianne Williamson, radio personality and 
      author of The Ages of Miracles: Embracing 
      the New Midlife.
    
    
      As many as 12,000 attendees will have a chance to see Cardiovascular 
      Sciences’ flagship cell renewal anti-aging 
      supplement, Rejuven8 ™. 
      They will also have the opportunity to sample the Company’s 
      exclusive Hardy Heart NutZ ™, premium 
      granola-like mix, containing over 40 natural ingredients, including 
      various nuts, grains, seeds and exotic fruits. All the Company’s 
      products are displayed at the retail website, www.Rejuven8online.com.
    
    
      Attendees will also see the Company’s unique 
      new hingeless pillbox, containing compartments, compact but large 
      enough, to hold even the bulkiest of today’s 
      nutritional supplements.
    
    
      About Cardiovascular Sciences:
    
    
      Cardiovascular Sciences, Inc. is a medical device company, whose primary 
      focus is developing a novel technology platform, addressing problems of 
      post-surgical adhesion. Adhesions and their complications are 
      significant problems worldwide for a range of specialists, including 
      general, cardiothoracic, orthopedic, plastic, ophthalmologic and 
      otolaryngology specialists to name a few. In addition, the veterinary 
      field has tremendous need for a product that can prevent similar 
      problems in animals. The Company's unique materials and processes 
      promise more cost-effective and capable means to deal with a problem, 
      devastating to many. Sponsored research at UCF and previously elsewhere 
      indicates the Company is on the right path and progressing.
    
    
      In addition to anti-adhesion technology, the Company owns technology in 
      other areas, yielding a diversified portfolio with projects in various 
      developmental stages. One of these is represented by the company’s 
      antioxidant cell newel formula, Rejuven8 
      ™ and a line of complementary health 
      related offerings.
    
    
      Forward-looking statements here are made pursuant to Safe Harbor 
      Provisions of the Private Securities Litigation Reform Act of 1995. 
      These forward-looking statements are subject to certain risks and 
      uncertainties. Actual results could differ from those discussed. This 
      material is information only, not an offer or solicitation to buy or 
      sell the securities.